Morningstar

TriSalus Life Sciences Gets FDA Clearance for Drug Delivery Device

Provided by Dow Jones

By Elias Schisgall 




  TriSalus Life Sciences said it received Food and Drug Administration 510(k) clearance for a new pressure-enabled drug delivery device. 



  Shares surged 26% to $6.21 on the news after Tuesday's closing bell. The stock closed down 1% at $4.93 and is down 29% this year. 



  The oncology company said the FDA greenlit TriNav Advance, the latest addition to the company's PEDD portfolio. The new device has access to small, distal vessels using a microcatheter and completes the company's portfolio addressing liver-directed therapy cases, TriSalus said. 



  The company will launch a limited market release of the device in the coming weeks. 



  "TriNav Advance enhances our Pressure-Enabled Drug Delivery portfolio in support of the full range of liver embolization procedures," Chief Executive Mary Szela said. "We are proud of the range of tools we offer to physicians and believe TriNav Advance will catalyze further adoption across these procedures. We're excited to broaden our portfolio in a way that can meaningfully benefit both physicians and patients." 





  Write to Elias Schisgall at elias.schisgall@wsj.com 





  (END) Dow Jones Newswires



  September 22, 2026 17:10 ET (21:10 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
The 10 Best Companies to Invest in Now
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
 
Russ Kinnel shares investment ideas from his annual Thrilling Funds list and discusses how he screens for quality investments in a sea of options. 
 
 
Russel Kinnel and Ivanna Hampton 
 
 
 
4 Stocks to Buy Before They Rise Further
 
Plus, the member of the triple-digit club reporting earnings this week. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
The Top Funds for a Simpler Retirement Portfolio
 
For retirement savers and retirees, Christine Benz highlights all-in-one funds and core funds that can serve as building blocks for a streamlined portfolio. 
 
 
Christine Benz 
 
 
 
The 10 Best Dividend Stocks
 
These are the top dividend-paying stocks to buy today. 
 
 
Susan Dziubinski 
 
 
 
 

			Sponsor Center